South Africa is asking local drugmakers to start a process to make Gilead Sciences’ long-acting HIV prevention drug, ...

South Africa’s National Aids Council, Sanac, has asked local drug companies to submit applications by April 7 to make generic ...

South Africa’s National Aids Council, Sanac, has asked local drug companies to submit applications by April 7 to make generic versions of an anti-HIV jab that could end Aids by 2043 in the country.

It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

The Health Department warns that a viral post claiming a R1 200 HIV grant for HIV-positive citizens from May 2026 is false.

Gilead Sciences (GILD) stock is in focus as the biotech is in talks with South Africa to manufacture twice-yearly HIV drug lenacapavir locally. Read more here.

South Africa has the world’s highest HIV burden, with about 8 million HIV-positive people, or 1 in 5 adults, as of last year.

South Africa's National Aids Council, Sanac, has asked local drug companies to submit applications by April 7 to make generic versions of an anti-HIV jab that could end Aids by 2043 in the country.

The Department of Health debunks false R1,200 HIV grant claims on social media, urging South Africans to verify information ...

Academy Award-winning actress and Dior Beauty ambassador Charlize Theron has long been a passionate advocate for her native ...

Vaccine development remains central to reducing incident HIV globally, particularly where long-acting PrEP access is limited, with therapeutic and preventive approaches advancing in parallel.